Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn

More articles from Drug Discovery and Translational Medicine

  • Open Access
    Discovery of M5049: A Novel Selective Toll-Like Receptor 7/8 Inhibitor for Treatment of Autoimmunity
    Jaromir Vlach, Andrew T. Bender, Melinda Przetak, Albertina Pereira, Aditee Deshpande, Theresa L. Johnson, Sonja Reissig, Evgeni Tzvetkov, Djordje Musil, Noune Tahmassian Morse, Philipp Haselmayer, Simone C. Zimmerli, Shinji L. Okitsu, Robert L. Walsky and Brian Sherer
    Journal of Pharmacology and Experimental Therapeutics March 2021, 376 (3) 397-409; DOI: https://doi.org/10.1124/jpet.120.000275
  • You have access
    Pharmacology and Mechanism of Action of HSK16149, a Selective Ligand of α2δ Subunit of Voltage-Gated Calcium Channel with Analgesic Activity in Animal Models of Chronic Pain
    Xiaoli Gou, Xiaojuan Yu, Dongdong Bai, Bowei Tan, Pingfeng Cao, Meilin Qian, Xiaoxiao Zheng, Lei Chen, Zongjun Shi, Yao Li, Fei Ye, Yong Liang and Jia Ni
    Journal of Pharmacology and Experimental Therapeutics March 2021, 376 (3) 330-337; DOI: https://doi.org/10.1124/jpet.120.000315
  • Improved Inhibitory and Absorption, Distribution, Metabolism, Excretion, and Toxicology (ADMET) Properties of Blebbistatin Derivatives Indicate That Blebbistatin Scaffold Is Ideal for drug Development Targeting Myosin-2
    Open Access
    Improved Inhibitory and Absorption, Distribution, Metabolism, Excretion, and Toxicology (ADMET) Properties of Blebbistatin Derivatives Indicate That Blebbistatin Scaffold Is Ideal for drug Development Targeting Myosin-2
    Máté Gyimesi, Anna Á. Rauscher, Sharad Kumar Suthar, Kamirán Á. Hamow, Kinga Oravecz, István Lőrincz, Zsolt Borhegyi, Máté T. Déri, Ádám F. Kiss, Katalin Monostory, Pál Tamás Szabó, Suman Nag, Ivan Tomasic, Jacob Krans, Patrick J. Tierney, Mihály Kovács, László Kornya and András Málnási-Csizmadia
    Journal of Pharmacology and Experimental Therapeutics March 2021, 376 (3) 358-373; DOI: https://doi.org/10.1124/jpet.120.000167
  • You have access
    Inhibiting Sialidase-Induced TGF-β1 Activation Attenuates Pulmonary Fibrosis in Mice
    Tejas R. Karhadkar, Thomas D. Meek and Richard H. Gomer
    Journal of Pharmacology and Experimental Therapeutics January 2021, 376 (1) 106-117; DOI: https://doi.org/10.1124/jpet.120.000258
  • Open Access
    Mechanistic Analysis of an Extracellular Signal–Regulated Kinase 2–Interacting Compound that Inhibits Mutant BRAF-Expressing Melanoma Cells by Inducing Oxidative Stress
    Ramon Martinez, Weiliang Huang, Ramin Samadani, Bryan Mackowiak, Garrick Centola, Lijia Chen, Ivie L. Conlon, Kellie Hom, Maureen A. Kane, Steven Fletcher and Paul Shapiro
    Journal of Pharmacology and Experimental Therapeutics January 2021, 376 (1) 84-97; DOI: https://doi.org/10.1124/jpet.120.000266
  • Characterization of Negative Allosteric Modulators of the Calcium-Sensing Receptor for Repurposing as a Treatment of Asthma
    You have access
    Characterization of Negative Allosteric Modulators of the Calcium-Sensing Receptor for Repurposing as a Treatment of Asthma
    Polina L. Yarova, Ping Huang, Martin W. Schepelmann, Richard Bruce, Rupert Ecker, Robert Nica, Vsevolod Telezhkin, Daniela Traini, Larissa Gomes dos Reis, Emma J. Kidd, William R. Ford, Kenneth J. Broadley, Benson M. Kariuki, Christopher J. Corrigan, Jeremy P.T. Ward, Paul J. Kemp and Daniela Riccardi
    Journal of Pharmacology and Experimental Therapeutics January 2021, 376 (1) 51-63; DOI: https://doi.org/10.1124/jpet.120.000281
  • You have access
    Downregulation of Interferon-γ Receptor Expression Endows Resistance to Anti–Programmed Death Protein 1 Therapy in Colorectal Cancer
    Chunxiao Lv, Dongfen Yuan and Yanguang Cao
    Journal of Pharmacology and Experimental Therapeutics January 2021, 376 (1) 21-28; DOI: https://doi.org/10.1124/jpet.120.000284
  • You have access
    Monoclonal Antibodies Counteract Opioid-Induced Behavioral and Toxic Effects in Mice and Rats
    Carly Baehr, April Huseby Kelcher, Aaron Khaimraj, Dana E. Reed, Sujata G. Pandit, David AuCoin, Saadyah Averick and Marco Pravetoni
    Journal of Pharmacology and Experimental Therapeutics December 2020, 375 (3) 469-477; DOI: https://doi.org/10.1124/jpet.120.000124
  • You have access
    Activation of Naturally Occurring Lecithin:Cholesterol Acyltransferase Mutants by a Novel Activator Compound
    Chiara Pavanello, Alice Ossoli, Marta Turri, Arianna Strazzella, Sara Simonelli, Tommaso Laurenzi, Keita Kono, Keisuke Yamada, Naoki Kiyosawa, Ivano Eberini and Laura Calabresi
    Journal of Pharmacology and Experimental Therapeutics December 2020, 375 (3) 463-468; DOI: https://doi.org/10.1124/jpet.120.000159
  • Mechanism of Action of Veverimer: A Novel, Orally Administered, Nonabsorbed, Counterion-Free, Hydrochloric Acid Binder under Development for the Treatment of Metabolic Acidosis in Chronic Kidney Disease
    Open Access
    Mechanism of Action of Veverimer: A Novel, Orally Administered, Nonabsorbed, Counterion-Free, Hydrochloric Acid Binder under Development for the Treatment of Metabolic Acidosis in Chronic Kidney Disease
    Gerrit Klaerner, Jun Shao, Kalpesh Biyani, Matthew Kade, Paul Kierstead, Randi Gbur, Scott Tabakman, Son Nguyen and Jerry Buysse
    Journal of Pharmacology and Experimental Therapeutics December 2020, 375 (3) 439-450; DOI: https://doi.org/10.1124/jpet.120.000190

Pages

  • Previous
  • Next
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • …
  • 51
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics